Genetic Engineering & Biotechnology News

SEP15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/869753

Contents of this Issue

Navigation

Page 8 of 77

Genetic Engineering & Biotechnology News | GENengnews.com | SEPTEMBER 15, 2017 | 7 is optimizing its global product availability. This entails integrating product lines so the full catalog of products is available through each of the three companies and that prod- ucts are prepositioned in the U.S. and the Eu- rope, and also are readily available through their distributors in the Asian Pacific and Latin American markets. Koi did not go into detail about the other aspects of corporate integration, but anyone who has gone through a merger has a good idea of what's involved. Linking internal sys- tems for data sharing and ordering, retrain- ing the sales force, realigning staff, and craft- ing an inclusive corporate culture are just a few of the typical, behind-the-scenes, post- merger activities for any company. Hinting at this, Koi says his mission is to blend cor- porate cultures and articulate to the work- force exactly what the newly stated corpo- rate values of "passion, precision, creativity, and trust," mean in their day-to-day work, at every level throughout the company. Three Centuries of Combined History Duran was founded in 1893 as Glastech- nische Laboratorium Schott & Genossen Jena (now Schott) when founder Otto Schott revolutionized labware with the development of glass made from borosilicate rather than the soda-lime or lead glassware common at that time. The new glass made it possible for scientists to measure temperatures up to 500 degrees Celsius. Otto Schott recruited physi- cist Ernst Abbe and optics pioneer Carl Zeiss as cofounders. In 1938 in Berlin, the glass was registered as the Duran ® brand to dif- ferentiate between laboratory and consumer applications of the glass. Eventually, the Du- ran brand would boast some 5,000 standard lab products. In 2005, 112 years after borosilicate glass was developed, the Duran Group was spun out of Schott AG and acquired by the Munich investor Adcuram Group. Adcuram's involve- ment helped Duran attain a 70% share of the global labware market. When Duran was sold in 2014, it was in a strong position to chart its own fate. A few months later, in 2015, it ac- quired Wheaton and, in 2016, Kimble Chase. In 2017, it renamed the group, believing, Koi says, that "each of the three companies is equally important and more relevant because of their combined strengths." Wheaton was founded in 1888 by Theo- dore Corson Wheaton, M.D., as T.C. Whea- ton in Millville, NJ. The company became known as a glass innovator. It overcame the challenges of Great Depression by automat- ing, which allowed it to grow. It remained a family company until 1996, when it was acquired by Algroup, which was acquired by Alcan of Canada in 2000. The assets of a spinoff company (which filed for bankruptcy in 2005) were acquired by Gujarat Glass in India and Kimble Glass, by then a subsidiary of the Gerresheimer Group in Germany. At that point, in 2006, the group spun- off Wheaton Science Products, which was renamed Wheaton Industries. The spin-off heralded innovation in labware for research, diagnostic packaging, and specialty pharma- ceuticals industries. Kimble Chase also has a century of inno- vation behind it. Founded as Kimble Glass ® in Chicago, it became a source of volumetric glassware for scientific labs. The company op- erated independently until 1997, when it was acquired by the Gerresheimer Group. Kimble Chase Life Science and Research LLC was formed in 2007 in a joint venture between its parent company and ThermoFisher. David Koi, president and CEO of DWK Life Sciences, is the former senior vice presi- dent of global portfolio management at Fisher Scientific. … I could utilize cells from the same donor over a long time period? … immune cells could be modified non-virally in large scale ? … I beat my boss at tennis tonight, will he get mad at me? What if... BioResearch www.lonza.com / immuno-therapy ©2017 Lonza. All trademarks belong to Lonza or its affiliates. The information contained herein is believed to be correct. No warranty is made, either expressed or implied. Solving Today's Challenges in Immunotherapy Lonza can't help you with your temperamental boss, but we can provide high quality primary cells, transfection technology and services to support your transition from research into therapy. – Large inventory of primary blood cells from individual donors – NEW! Large-scale transfection of 10 9 primary immune and stem cells – Clinical development and commercial manufacturing services for cell therapies Visit our website for immunotherapy-related technical resources. 4D-Nucleofector™ LV Unit for large-scale transfection Corporate Profile DWK Life Sciences Location 1501 North Tenth St. Millville, NJ 08332 Phone (856) 825-1100 Website www.dwk-lifesciences.com Principal David Koi CEO and President Number of Employees 1,700 (globally) Focus DWK Life Sciences develops premium labware, including disposable products and customized solutions for scientific applications. Vital Signs

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - SEP15 2017